Merck Stock News

Paxlovid is the decisive factor, and Comirnaty''s bound to help too.

Privately-held Curve Therapeutics has inked a contract with Merck & Co Inc (NYSE: MRK ) to discover and validate modulators of up to five therapeutic targets using its Microcycle technology, initially for oncology and neurology indications. Under the agreement terms, Curve will receive an upfront payment and be eligible to receive … Full story available on Benzinga.com

Limited efficacy means it is increasingly seen as a therapy for those who cannot take rival medications

A2Z Market Research published new research on Global Pet Speciality Drugs covering micro level of analysis by competitors and key business segments (2022-2029). The Global Pet Speciality Drugs explores comprehensive study on various segments like opportunities, size, development, innovation, sales

BioXcel Therapeutics Inc (NASDAQ: BTAI ) announced results from its ongoing Phase 2 trial of BXCL701 in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype. Results will be highlighted in two poster presentations at the 2022 ASCO Genitourinary Cancers Symposium. The trial is evaluating the combination of BXCL701 with Merck & Co Inc''s (NYSE: MRK ) Keytruda (pembrolizumab). SCNC Findings: In the evaluable patient cohort (n = 15),

WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Peptide Cancer Vaccine Market finds that Peptide Cancer Vaccine aids to provide tumour-specific T-cells to control or eradicate cancer. This vaccine contains tumour antigens in the form of short or long amino acid sequences. The usage of Peptide Cancer Vaccine to control tumour growth in mouse models is expected to propel the growth of Peptide Cancer Vaccine Market in upcoming years. The total Global Peptide Cancer Vaccine Market is estimated to reach USD 10.07 Billion by 2028. The revenue of the market was USD 4.72 Billion in the year 2021, and is expected to reach with a Compound Annual Growth Rate (CAGR) of 11.2%, states Vantage Market Research, in a report, titled "Peptide Cancer Vaccine Market by Application (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer), by Type (Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Peptide Cocktail Type, Multivalent Peptide Vaccine), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA + Abiraterone Reduced Risk of Disease Progression or Death by 34% vs Abiraterone in 1L Metastatic Castration-Resistant Prostate Cancer

If there''s one thing recent macroeconomic and stock market turbulence should reteach us, it''s that the best blue-chip dividend stocks never go out of style. And the Dow''s best dividend stocks are proving that handily so far in 2022. True, inflation is advancing at the fastest pace in four decades, and the market is seething with anxiety over impending interest rate hikes. Yet the top-rated dividend payers among the 30 Dow Jones stocks are beating the market so far this year and should continue to give income investors some much-needed peace of mind. SEE MORE The Pros Picks: 22 Top Stocks to Invest In for 2022 Many of the Dow''s best dividend stocks also happen to be dividend growth stalwarts. Quite a few names in this elite bastion of 30 blue-chip equities are members of the S&P 500 Dividend Aristocrats an index of 66 best dividend stocks that have increased their payouts for at least 25 consecutive years. It''s also noteworthy that the Dow Jones'' best dividend stocks hail from sectors that hold up well when inflation runs hot .

Read more Merck Closed Yesterday Down -1.93% The post Merck Closed Yesterday Down -1.93% appeared first on CFDTrading .

The "Cathepsin K/S Inhibitor - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com''s offering. "Cathepsin K/S Inhibitor - Pipeline Insight, 2022" report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cathepsin K/S Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Descriptive coverage of pipeline development activities for Cathepsin K/S Inhibitor Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and … Full story available on Benzinga.

Related Stocks: MRK , VICI , EVRG , CMCSA , TXN , NI , INTC , NRG , C , BSX , DTE , WY , ATVI , BNS , SBUX , YUM , OMC , TMX ,

Both the qualitative and quantitative features of the business in each and every country are covered in the Human Papillomavirus (HPV) Vaccines market research. Granular level data in the report covers market size, market share, historical development and key

Someone with a lot of money to spend has taken a bullish stance on Merck & Co (NYSE: MRK ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with MRK, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 18 uncommon options trades for Merck & Co. This isn''t normal. The overall sentiment of these big-money traders is split between 66% bullish and 33%, bearish. Out of all of the special options we uncovered, 13 are puts, for a total amount of $969,120, and 5 are calls, for a total Full story available on Benzinga.com